IL6 and COVID-19: ,18 The correlation of IL-6 with disease severity led to early clinical trials studying potential COVID-19 therapies; however, anti-IL-6 antibodies were not successful as therapy once patients were admitted, suggesting that the role of IL-6 in monocytic inflammation occurs before patients arrive at the hospital.19–21